Tempest Therapeutics (TPST)
NASDAQ:TPST
Want to see TPST full AI Analyst Report?
Top Page
Tempest Therapeutics
(NASDAQ:TPST)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▼(-48.98% Downside)
Action:Reiterated
Date:06/05/26
The score is weighed down primarily by weak financial performance (no revenue, widening losses, ongoing burn) and a significantly weakened balance sheet with elevated leverage and dilution/listing risk. Technicals also reflect a strong downtrend, partially tempered by oversold readings. Corporate events are mixed, with encouraging clinical data and incremental financing but notable Nasdaq compliance and governance concerns.
Positive Factors
Strong TPST-2003 clinical efficacy
TPST-2003 produced a 100% complete response rate in 15 CAR-T‑naïve evaluable patients with favorable safety and median PFS of 23.1 months. Durable early efficacy and tolerability support discussions toward a registrational pathway and strengthen the program's strategic potential for long-term development and partnership.
Negative Factors
Severely weakened balance sheet
Equity shrank to roughly $0.8M while debt remains about $7.9M, producing an acute ~9.6x debt-to-equity ratio and compressed assets (~$10.7M). This materially limits financial flexibility, raises refinancing probability, and increases the risk that future fundraising will be dilutive or covenant-constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TPST-2003 clinical efficacy
TPST-2003 produced a 100% complete response rate in 15 CAR-T‑naïve evaluable patients with favorable safety and median PFS of 23.1 months. Durable early efficacy and tolerability support discussions toward a registrational pathway and strengthen the program's strategic potential for long-term development and partnership.
Read all positive factors
Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.51M
Dividend YieldN/A
Average Volume (3M)50.79K
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue GrowthN/A
EPS Growth65.65%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.21
Shares Outstanding14,806,997
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.58
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$11.00Price Target Upside461.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Tempest Therapeutics Business Overview & Revenue Model
Company Description
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a...
How the Company Makes Money
Tempest Therapeutics does not have product revenue from marketed drugs and therefore does not generate recurring sales income from commercialized therapeutics. Its ability to generate cash typically depends on external financing and, where applica...
Tempest Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.25M | 0.00 | -389.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -42.83M | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M |
| Net Income | -43.10M | -26.26M | -41.84M | -29.49M | -35.71M | -28.30M |
Balance Sheet | ||||||
| Total Assets | 10.75M | 16.93M | 41.49M | 51.60M | 46.09M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 1.80M | 7.71M | 30.27M | 39.23M | 31.23M | 51.83M |
| Total Debt | 7.85M | 8.14M | 15.37M | 20.66M | 22.11M | 18.54M |
| Total Liabilities | 9.93M | 10.26M | 22.36M | 24.84M | 27.98M | 37.12M |
| Stockholders Equity | 822.00K | 6.67M | 19.13M | 26.77M | 18.11M | 36.12M |
Cash Flow | ||||||
| Free Cash Flow | -26.38M | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M |
| Operating Cash Flow | -26.38M | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M |
| Investing Cash Flow | 0.00 | 0.00 | -435.00K | -170.00K | -562.00K | -97.00K |
| Financing Cash Flow | 6.68M | 4.26M | 24.50M | 35.60M | 11.40M | 59.06M |
Tempest Therapeutics Technical Analysis
Negative
1.96
Price Trends
1.76
Negative
2.05
Negative
4.70
Negative
Market Momentum
-0.18
Positive
29.22
Positive
7.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 1.96 is above the 20-day moving average (MA) of 1.58, above the 50-day MA of 1.76, and below the 200-day MA of 4.70, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 29.22 is Positive, neither overbought nor oversold. The STOCH value of 7.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.
Tempest Therapeutics Risk Analysis
Tempest Therapeutics disclosed 77 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tempest Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $46.01M | ― | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $59.16M | ― | -346.03% | ― | ― | 28.53% | |
45 Neutral | $14.08M | -0.68 | -526.36% | ― | ― | 16.33% | |
43 Neutral | $32.63M | -1.38 | -218.67% | ― | ― | 48.96% | |
42 Neutral | $18.51M | -0.32 | -309.60% | ― | ― | 65.65% |
* Healthcare Sector Average
TPST
Tempest Therapeutics
1.25
-5.86
-82.42%
ATNM
Actinium Pharmaceuticals
1.04
-0.55
-34.59%
PDSB
PDS Biotechnology
1.12
-0.67
-37.43%
LTRN
Lantern Pharma
4.07
0.84
26.01%
CALC
CalciMedica
0.89
-0.86
-49.09%
Tempest Therapeutics Corporate Events
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Tempest Therapeutics Announces CFO Transition and Board Changes
Neutral
Jun 4, 2026
On May 29, 2026, Tempest Therapeutics disclosed that Chief Financial Officer Nicholas Maestas had resigned effective June 5, 2026, and on that date the board appointed longtime finance executive Justin Trojanowski as Vice President, Finance, Princ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tempest Therapeutics Executes Warrant-Inducement Equity Financing Deal
Neutral
Jun 2, 2026
On May 28, 2026, Tempest Therapeutics entered into an inducement agreement with a holder of warrants originally issued in November 2025, cutting the exercise price from $3.50 to $1.73 per share in exchange for the holder exercising warrants for 1,...
Executive/Board Changes
Tempest Therapeutics Announces Resignation of Board Director
Neutral
May 29, 2026
On May 23, 2026, Tempest Therapeutics, Inc. announced that Ms. Simantov resigned from its Board of Directors, with the company stating it had not been informed of any disagreement related to its operations, policies, or practices underlying her de...
Executive/Board ChangesDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks
Negative
May 22, 2026
On May 19, 2026, Tempest Therapeutics received a deficiency notice from Nasdaq after reporting stockholders’ equity of $822,000 as of March 31, 2026, far below the $2.5 million minimum required for continued listing on the Nasdaq Capital Mar...
Executive/Board Changes
Tempest Therapeutics Announces Multiple Board Director Resignations
Neutral
May 22, 2026
On May 22, 2026, Tempest Therapeutics, Inc. announced that directors Stephen Brady, Michael Raab and Christine Pellizzari resigned from its board of directors, with the company stating it had not been informed of any disagreements related to opera...
Business Operations and StrategyProduct-Related Announcements
Tempest Therapeutics Showcases Strong TPST-2003 CAR-T Data
Positive
May 6, 2026
On May 6, 2026, Tempest Therapeutics reported new clinical data at the ISCT 2026 meeting in Dublin from its lead dual-targeting CAR-T candidate TPST-2003, showing a 100% complete response rate among 15 CAR-T-naïve efficacy evaluable patients ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tempest Therapeutics Announces Private Placement Financing Agreement
Positive
Mar 23, 2026
Tempest Therapeutics entered into a securities purchase agreement on March 20, 2026 with two institutional investors and Factor Bioscience for a private placement of 462,964 common shares and pre-funded warrants for up to 462,963 additional shares...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.